Astrazeneca Share News (AZN)

UPDATE 3-AstraZeneca sees big healthcare changes under Trump

* First full quarter of Crestor generics in U.S. market * Tax gain, cost cuts, externalisation offset sales fall * Q3 revenue $5.7 billion vs consensus $5.9 billion * Q3 core EPS $1.32 vs consensus 97 cents (Adds comments by CEO on U.S. market, analyst's comment, updates share

AstraZeneca drops early head and neck cancer drug plans

LONDON, Nov 10 (Reuters) - AstraZeneca said on Thursday it had given up on the idea of seeking an early approval of its immunotherapy drug durvalumab in head and neck cancer using mid-stage Phase II clinical trials data. The move follows recent changes in the competitive landscape, which ha

Astrazeneca reports worse-than-expected drop in Q3 revenue

(ShareCast News) - Astrazeneca shares edged lower on Thursday as it reported a worse-than-expected drop in third quarter revenue. Revenue fell 4% to $5.7bn in the three months ended 30 September, missing forecasts of $5.87bn, as cheaper generic versions of its best-selling medicine Crestor hurt sale

UPDATE 2-Tax gain and cost cuts help AstraZeneca offset flagging Crestor

* First full quarter of Crestor generics in U.S. market * Tax gain, cost cuts, externalisation offset sales fall * Q3 revenue $5.7 billion vs consensus $5.9 billion * Q3 core EPS $1.32 vs consensus 97 cents (Adds shares, further details on tax gain) By Ben Hirschler <

UPDATE 1-AstraZeneca offsets flagging Crestor with cost cuts, disposals

* First full quarter of Crestor generics in U.S. market * Cost cutting and externalisation offset weaker sales * Q3 revenue $5.7 billion vs consensus $5.9 billion * Q3 core EPS $1.32 vs consensus 97 cents (Adds CEO comment, further details on sales and pipeline) By Ben H

TOP NEWS: AstraZeneca Keeps Guidance As Crestor Generics Hit Revenue

AstraZeneca's drug sales weighed on by flagging Crestor

LONDON, Nov 10 (Reuters) - Competition from multiple generic versions of its cholesterol fighter Crestor hit AstraZeneca's third-quarter sales but the drugmaker mitigated the damage with income from disposals and good growth in new products. Revenue declined 4 percent $5.7 billion but core

UPDATE 4-Pharma, biotech shares soar as Trump win calms pricing talk

* Clinton had been seen more likely to rein in drug costs * California drug pricing initiative heading for defeat * Hospital shares crushed on Obamacare rollback worries (Adds background on biotechs, analyst comment, updates share moves) By Lewis Krauskopf and Ben Hirschler</p

Britain's FTSE recovers from Trump shock to hit one-week high

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 index closes 1 pct higher * Miners, pharma stocks rally * U.S.-exposed firms also gain By Atul Prakash and Kit R

UPDATE 3-Pharma, biotech shares soar as Trump win calms pricing fears

* Clinton had been seen more likely to rein in drug costs * California drug pricing initiative heading for defeat * Hospital shares crushed on Obamacare rollback worries (Updates with open of U.S. markets; adds hospital, insurer reactions, analyst comments, dateline) By Lewis

Analysts pick winners as pharma sector bounces back on Clinton loss

(ShareCast News) - The pharmaceuticals sector bounced back after Donald Trump won the battle to become the next president of the United States and the Republican party won control of Congress, with analysts suggesting AstraZeneca, Shire and Eli Lilly were among the best placed stocks to capitalise o

UPDATE 2-Trump win boosts drug stocks as prospect of price curbs recedes

* Clinton had been seen more likely to rein in drug costs * California drug pricing initiative also heading for defeat * European sector gains 3 pct, U.S. stocks up in premarket * EpiPen maker Mylan jumps 8 percent in Tel Aviv (Adds U.S. pre-market trade, further fund manager

Thursday preview: Astrazeneca to report decline in third quarter sales

(ShareCast News) - Astrazeneca is expected to report a drop in third quarter sales on Thursday after failing to prevent generic drug makers from bringing cheaper rivals of its best-selling medicine Crestor. Analysts expect generic versions of cholesterol fighting drug Crestor will have sent revenue

UPDATE 1-Trump win boosts drug stocks as prospect of price curbs recedes

* Clinton had been seen more likely to rein in drug costs * California drug pricing initiative also heading for defeat * Shares in big European drugmakers up 2 to 6 percent * EpiPen maker Mylan soars 8 percent in Tel Aviv (Adds more reaction, Mylan shares, Novo Nordisk comment

Britain's FTSE dips after Trump win though pharma, gold miners surge

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 down 0.1 pct * Gold miners, pharma stocks rally * U.S.-exposed firms also gain By Kit Rees LONDON, Nov 9 (